---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061271"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:21:32.293429+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025

## Summary
- Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.
- Cash $11.1M at Sep 30; after $23.9M ATM net proceeds, preliminary cash $32.8M extending runway into 2025.
- TPST-1120 triplet arm cORR 30% vs 13.3% control; median PFS 7 mo vs 4.27 mo (HR 0.7); median OS not reached vs 15.1 mo (HR 0.59).
- Plan to advance TPST-1120 into registrational study in first-line HCC, likely with a partner.
- Adopted limited-duration stockholder rights plan on Oct 10, 2023 to deter hostile accumulation.

## SEC filing metadata
- accession: 0000950170-23-061271
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/tpst-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061271
- JSON: https://secwatch.observer/filing/0000950170-23-061271.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061271.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported the nine months ended September 30, 2023 results: net income $22.0 million, EPS $1.57 per share.
  - Period: the nine months ended September 30, 2023
  - Net income: $22.0 million
  - EPS: $1.57 per share
  - Result: reported results
  source text: Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm
- Earnings Releases
  Tempest Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income $6.8 million, EPS $0.48 per share.
  - Period: the quarter ended September 30, 2023
  - Net income: $6.8 million
  - EPS: $0.48 per share
  - Result: reported results
  source text: Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.